Since the approval of the first gene therapy for blindness, there has been a wave of companies developing gene therapy treatments with the potential to cure different forms of genetic…
The big US biotech Biogen has agreed to acquire Nightstar Therapeutics for €773M ($877M), including Nightstar’s candidate gene therapies for inherited blindness. Expected to be complete by mid-2019, Biogen’s acquisition…
UK startup Nightstar Therapeutics has reported good safety and early signs of visual improvements in a Phase I/II trial with a gene therapy for a rare form of inherited blindness.…
Nightstar Therapeutics will begin the first Phase III trial for a gene therapy targeting choroideremia, a rare disorder leading to complete blindness. Nightstar will launch the first-ever Phase III trial testing…
As the 2017 reports roll in, we're already turning our gaze to 2018. These are the top European biotech companies to watch in the new year. The results from last…
Nightstar has gone public on the American market with the aim of raising $75M for its gene-based retinal disease cures. Spun out from Oxford in 2013, Nightstar is developing and commercializing…
NightstaRx has raised €39.5M that will go towards three clinical programs testing gene therapies for rare diseases that cause blindness. NightstaRx is developing gene therapies for genetic retinal diseases that…
Choroideremia is a rare X-linked recessive retinal disease which eventually leads to blindness. A series B funding round has landed the NightstaRx ('Nightstar') biotech in Oxford an additional $35M for…